Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

compulsory licence

- PMLiVE

Amgen and Kite in $1bn cancer immunotherapy tie up

Latest major research deal in growing area of oncology

Bristol-Myers Squibb (BMS) building

BMS cancer drug Opdivo gains US melanoma licence

Therapeutic vaccine can now be used against the deadliest form of skin cancer

- PMLiVE

Double trial disappointment for Roche

Discontinues Alzheimer’s programme and finds Kadcyla no better than Herceptin in certain breast cancer

Roche - Basel

Roche leads pharma R&D spend for 2013

Top 30 pharma companies spent a total of $112bn on research

- PMLiVE

First biosimilar Humira launches in India

AbbVie to face competition for world’s biggest-selling drug

- PMLiVE

UCB’s $1.53bn generics sale falls through

Advent and Avista Capita back away from bid to acquire Kremers Urban due to unanticipated conflict in timing

- PMLiVE

NICE backs Pfizer drug in kidney cancer

Inlyta near end of two-year struggle for recommendation

- PMLiVE

Roche and Exelixis file melanoma duo in US

Combination of cobimetinib and Zelboraf improved progression-free survival by 9.9 months

- PMLiVE

Roche’s early development head Richard Scheller to retire

Will be replaced by Michael Varney from the company's Genentech business

- PMLiVE

Cancer care celebrated at awards

QiC Oncology programme recognises teams working to improve patient outcomes in oncology

- PMLiVE

Roche appoints business director in Spain

Promotion for Rosi Vivancos

Bristol-Myers Squibb (BMS) building

BMS to fund hepatitis projects in China and India

Pharma firm awards nine grants to support care for high-risk patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links